Hemostemix Announces Lead Order of $1,500,000 and the Full Repayment of $2,500,000 Convertible Debenture
Hemostemix (OTCQB: HMTXF) announced a significant financial restructuring, with Chairman Peter Lacey providing a $1.5 million lead order for a non-brokered private placement at $0.10 per Unit. Each Unit includes one Common Share and one Warrant exercisable at $0.15 for two years. $1.25 million will be used to fully repay a $2.5 million Convertible Debenture.
The placement is part of a larger offering totaling up to $2.5 million. The company also confirmed the conversion price of previously announced ACP-01 Therapy Convertible Debentures (TCD) at CAD $0.155, relating to the March 5 sale of 15 TCDs for $708,605.
Hemostemix (OTCQB: HMTXF) ha annunciato una significativa ristrutturazione finanziaria, con il Presidente Peter Lacey che ha sottoscritto un ordine principale da 1,5 milioni di dollari per un collocamento privato senza intermediari al prezzo di 0,10 dollari per Unità. Ogni Unità comprende un'Azione Ordinaria e un Warrant esercitabile a 0,15 dollari per due anni. 1,25 milioni di dollari saranno utilizzati per estinguere completamente un Debito Convertibile da 2,5 milioni di dollari.
Il collocamento fa parte di un'offerta più ampia che può arrivare fino a 2,5 milioni di dollari. L'azienda ha inoltre confermato il prezzo di conversione dei precedentemente annunciati Debiti Convertibili della Terapia ACP-01 (TCD) a 0,155 CAD, relativi alla vendita del 5 marzo di 15 TCD per un totale di 708.605 dollari.
Hemostemix (OTCQB: HMTXF) anunció una reestructuración financiera significativa, con el presidente Peter Lacey realizando una orden principal de 1,5 millones de dólares para una colocación privada sin intermediarios a 0,10 dólares por unidad. Cada unidad incluye una acción común y un warrant ejercitable a 0,15 dólares durante dos años. 1,25 millones de dólares se destinarán a pagar completamente un bono convertible de 2,5 millones de dólares.
La colocación forma parte de una oferta mayor que asciende hasta 2,5 millones de dólares. La compañía también confirmó el precio de conversión de los bonos convertibles de la terapia ACP-01 (TCD) anunciados previamente en 0,155 CAD, relacionados con la venta del 5 de marzo de 15 TCD por un total de 708.605 dólares.
Hemostemix (OTCQB: HMTXF)는 중대한 재무 구조조정을 발표했으며, 회장 Peter Lacey가 단위당 0.10달러의 비중개인 사모 발행을 위해 150만 달러의 선도 주문을 제공했습니다. 각 단위는 보통주 1주와 2년간 행사 가능한 행사가 0.15달러의 워런트 1개를 포함합니다. 125만 달러는 250만 달러 전환사채를 전액 상환하는 데 사용됩니다.
이번 발행은 총 250만 달러 규모의 더 큰 공모의 일부입니다. 회사는 또한 3월 5일에 판매된 15개의 ACP-01 치료 전환사채(TCD)와 관련된 전환 가격을 CAD 0.155로 확정했다고 밝혔으며, 총액은 708,605달러입니다.
Hemostemix (OTCQB : HMTXF) a annoncé une restructuration financière majeure, avec le président Peter Lacey fournissant un ordre principal de 1,5 million de dollars pour un placement privé sans courtier à 0,10 dollar par unité. Chaque unité comprend une action ordinaire et un warrant exerçable à 0,15 dollar pendant deux ans. 1,25 million de dollars seront utilisés pour rembourser intégralement une obligation convertible de 2,5 millions de dollars.
Le placement fait partie d'une offre plus large totalisant jusqu'à 2,5 millions de dollars. La société a également confirmé le prix de conversion des obligations convertibles de la thérapie ACP-01 (TCD) annoncées précédemment à 0,155 CAD, concernant la vente du 5 mars de 15 TCD pour un montant de 708 605 dollars.
Hemostemix (OTCQB: HMTXF) gab eine bedeutende finanzielle Umstrukturierung bekannt, wobei Vorsitzender Peter Lacey eine Führungsorder über 1,5 Millionen US-Dollar für eine nicht vermittelte Privatplatzierung zu 0,10 US-Dollar pro Einheit bereitstellte. Jede Einheit umfasst eine Stammaktie und einen Warrant, der für zwei Jahre zu 0,15 US-Dollar ausübbar ist. 1,25 Millionen US-Dollar werden verwendet, um eine 2,5 Millionen US-Dollar Convertible Schuldverschreibung vollständig zurückzuzahlen.
Die Platzierung ist Teil eines größeren Angebots, das sich auf bis zu 2,5 Millionen US-Dollar beläuft. Das Unternehmen bestätigte außerdem den Wandlungspreis der zuvor angekündigten ACP-01 Therapie Convertible Schuldverschreibungen (TCD) bei 0,155 CAD, bezogen auf den Verkauf von 15 TCDs am 5. März für insgesamt 708.605 US-Dollar.
- None.
- None.
Calgary, Alberta--(Newsfile Corp. - June 26, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") announces its Chairman, Peter Lacey, has provided the Company with a lead order for a non brokered private placement in the amount of
Certain directors of the Company are participating in the Offering, which constitutes a "related party transaction" within the meaning of Multilateral Instrument 61-101 - Protection of Minority Security Holders in Special Transactions ("MI 61-101") and the policies of the TSXV. The Company is relying upon the exemptions from the formal valuation and minority shareholder approval requirements pursuant to sections 5.5(b) and 5.7(1)(a), respectively, of MI 61-101 on the basis that the Company is not listed on a specified stock exchange and, at the time the Offering was agreed to, neither the fair market value of the subject matter of, nor the fair market value of the consideration for, the transaction insofar as it involves an interested party (within the meaning of MI 61-101) in the Offering, exceeds
Further to the March 5, 2025 news release announcing the sale of 15 ACP-01 Therapy Convertible Debentures (TCD) for proceeds of
The Company confirms that there is no material fact or material change about the Company that has not been generally disclosed.
ABOUT HEMOSTEMIX
Hemostemix is an autologous stem cell therapy platform company, founded in 2003. A winner of the World Economic Forum Technology Pioneer Award, the Company has developed, patented, is scaling and selling autologous (patient's own) blood-based stem cell therapies that include angiogenic cell precursors (ACP-01). Hemostemix has completed seven clinical studies of 318 subjects and published its results in nine peer reviewed publications. ACP-01 is safe, clinically relevant and statistically significant as a treatment for peripheral arterial disease, chronic limb threatening ischemia, non ischemic dilated cardiomyopathy, ischemic cardiomyopathy, congestive heart failure, and angina. Hemostemix completed its Phase II clinical trial for chronic limb threatening ischemia and published its results in the Journal of Biomedical Research & Environmental Science. As compared to a five year mortality rate of
For further information, please contact: Thomas Smeenk, President, CEO & Co-Founder
EM: tsmeenk@hemostemix.com PH: 905-580-4170
Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined under the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-Looking Information: This news release contains "forward-looking information" within the meaning of applicable Canadian securities legislation. All statements, other than statements of historical fact, included herein are forward-looking information. In particular, this news release contains forward-looking information in relation to a non brokered private placement and sales of its lead product ACP-01, the commercialization of ACP-01 via the sale of compassionate treatments under Special Access Programs. There can be no assurance that such forward-looking information will prove to be accurate. Actual results and future events could differ materially from those anticipated in such forward-looking information. This forward-looking information reflects Hemostemix's current beliefs and is based on information currently available to Hemostemix and on assumptions Hemostemix believes are reasonable. These assumptions include, but are not limited to: the underlying value of Hemostemix and its Common Shares; the successful resolution of any litigation that Hemostemix is pursuing or defending (the "Litigation"); the results of ACP-01 research, trials, studies and analyses, including the analysis being equivalent to or better than previous research, trials or studies; the receipt of all required regulatory approvals for research, trials or studies; the level of activity, market acceptance and market trends in the healthcare sector; the economy generally; consumer interest in Hemostemix's services and products; competition and Hemostemix's competitive advantages; and, Hemostemix obtaining satisfactory financing to fund Hemostemix's operations including any research, trials or studies, and any Litigation. Forward-looking information is Subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of Hemostemix to be materially different from those expressed or implied by such forward-looking information. Such risks and other factors may include, but are not limited to: the ability of Hemostemix to complete clinical trials, complete a satisfactory analyses and file the results of such analyses to gain regulatory approval of a phase II or phase III clinical trial of ACP-01; potential litigation Hemostemix may face; general business, economic, competitive, political and social uncertainties; general capital market conditions and market prices for securities; delay or failure to receive board or regulatory approvals; the actual results of future operations including the actual results of future research, trials or studies; competition; changes in legislation affecting Hemostemix; the timing and availability of external financing on acceptable terms; long-term capital requirements and future developments in Hemostemix's markets and the markets in which it expects to compete; lack of qualified, skilled labour or loss of key individuals; and risks related to the COVID-19 pandemic including various recommendations, orders and measures of governmental authorities to try to limit the pandemic, including travel restrictions, border closures, non-essential business closures service disruptions, quarantines, self-isolations, shelters-in-place and social distancing, disruptions to markets, disruptions to economic activity and financings, disruptions to supply chains and sales channels, and a deterioration of general economic conditions including a possible national or global recession or depression; the potential impact that the COVID-19 pandemic may have on Hemostemix which may include a decreased demand for the services that Hemostemix offers; and a deterioration of financial markets that could limit Hemostemix's ability to obtain external financing. A description of additional risk factors that may cause actual results to differ materially from forward-looking information can be found in Hemostemix's disclosure documents on the SEDAR+ website at www.sedarplus.ca. Although Hemostemix has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. Readers are cautioned that the foregoing list of factors is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking information as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Forward-looking information contained in this news release is expressly qualified by this cautionary statement. The forward-looking information contained in this news release represents the expectations of Hemostemix as of the date of this news release and, accordingly, it is Subject to change after such date. However, Hemostemix expressly disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities law.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/256886
